drugset

drugset / Trial / NCT00316654

Persistence of Antibody Response to N. Meningitidis Group C in Children

NCT00316654 ↗

Phase 4 Completed 489 enrolled Novartis Vaccines GlaxoSmithKline · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Persistence of Antibody Response to N. meningitidis Group C in Children

Timeline

Start: 2005-02
Primary completion: 2005-10
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Menjugate	Vaccine	—	—

Indications